I-Mab (IMAB) is priced at $3.57 after the most recent trading session. At the very opening of the session, the stock price was $3.78 and reached a high price of $3.7899, prior to closing the session it reached the value of $3.87. The stock touched a low price of $3.54.Recently in News on March 7, 2023, MSCI ESG Updated I-Mab to “A” Rating. I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted “A” rating by MSCI (Morgan Stanley Capital International) ESG, following MSCIESG’s most recent annual review, and such rating outperforms 66% peers among global biotech companies. You can read further details here
I-Mab had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $21.44 on 03/30/22, with the lowest value was $3.19 for the same time period, recorded on 12/28/22.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
I-Mab (IMAB) full year performance was -73.52%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, I-Mab shares are logging -83.35% during the 52-week period from high price, and 11.91% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.19 and $21.44.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 592271 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the I-Mab (IMAB) recorded performance in the market was -14.59%, having the revenues showcasing -6.05% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 299.09M, as it employees total of 378 workers.
The Analysts eye on I-Mab (IMAB)
During the last month, 0 analysts gave the I-Mab a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.49, with a change in the price was noted -0.22. In a similar fashion, I-Mab posted a movement of -5.80% for the period of last 100 days, recording 485,582 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for IMAB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of I-Mab (IMAB)
Raw Stochastic average of I-Mab in the period of last 50 days is set at 0.73%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.48%. In the last 20 days, the company’s Stochastic %K was 19.62% and its Stochastic %D was recorded 19.57%.
Considering, the past performance of I-Mab, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -14.59%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -32.89%, alongside a downfall of -73.52% for the period of the last 12 months. The shares increased approximately by -4.29% in the 7-day charts and went up by -26.24% in the period of the last 30 days. Common stock shares were lifted by -6.05% during last recorded quarter.